Skip to main content Accessibility help
×
Home

Effect of prior treatment with antipsychotic long-acting injection on randomised clinical trial treatment outcomes

  • Thomas R. E. Barnes (a1), Richard J. Drake (a2), Graham Dunn (a3), Karen P. Hayhurst (a2), Peter B. Jones (a4) and Shôn W. Lewis (a5)...

Abstract

Background

It is uncertain whether antipsychotic long-acting injection (LAI) medication in schizophrenia is associated with better clinical outcomes than oral preparations.

Aims

To examine the impact of prior treatment delivery route on treatment outcomes and whether any differences are moderated by adherence.

Method

Analysis of data from two pragmatic 1-year clinical trials in which patients with schizophrenia were randomised to either an oral first-generation antipsychotic (FGA), or a non-clozapine second-generation antipsychotic (SGA, CUtLASS 1 study), or a non-clozapine SGA or clozapine (CUtLASS 2 study).

Results

Across both trials, 43% (n = 155) of participants were prescribed an FGA-LAI before randomisation. At 1-year follow-up they showed less improvement in quality of life, symptoms and global functioning than those randomised from oral medication. This difference was confined to patients rated as less than consistently adherent pre-randomisation. The relatively poor improvement in the patients prescribed an LAI pre-randomisation was ameliorated if they had been randomised to clozapine rather than another SGA. There was no advantage to being randomly assigned from an LAI at baseline to a non-clozapine oral SGA rather than an oral FGA.

Conclusions

A switch at randomisation from an LAI to an oral antipsychotic was associated with poorer clinical and functional outcomes at 1-year follow-up compared with switching from one oral antipsychotic to another. This effect appears to be moderated by adherence, and may not extend to switching to clozapine. This has implications for clinical trial design: the drug from which a participant is randomised may have a greater effect than the drug to which they are randomised.

  • View HTML
    • Send article to Kindle

      To send this article to your Kindle, first ensure no-reply@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about sending to your Kindle. Find out more about sending to your Kindle.

      Note you can select to send to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be sent to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

      Find out more about the Kindle Personal Document Service.

      Effect of prior treatment with antipsychotic long-acting injection on randomised clinical trial treatment outcomes
      Available formats
      ×

      Send article to Dropbox

      To send this article to your Dropbox account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Dropbox.

      Effect of prior treatment with antipsychotic long-acting injection on randomised clinical trial treatment outcomes
      Available formats
      ×

      Send article to Google Drive

      To send this article to your Google Drive account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Google Drive.

      Effect of prior treatment with antipsychotic long-acting injection on randomised clinical trial treatment outcomes
      Available formats
      ×

Copyright

Corresponding author

Thomas R. E. Barnes, Centre for Mental Health, Imperial College, 37 Claybrook Road, London W6 8LN, UK. Email: t.r.barnes@imperial.ac.uk

Footnotes

Hide All

Declaration of interest

T.R.E.B. has received honoraria from Lilly and Roche for speaking at educational meetings. K.P.H. has received assistance to attend educational meetings from Novartis and Lilly. P.B.J. was a member of a scientific advisory board for Roche. S.W.L. has received honoraria from Janssen for speaking at educational meetings.

Footnotes

References

Hide All
1 Novick, D., Haro, JM, Suarez, D., Perez, V., Dittmann, RW, Haddad, PM. Predictors and clinical consequences of non-adherence with antipsychotic medication in the outpatient treatment of schizophrenia. Psychiatry Res 2010; 176: 109–13.
2 Barnes, TRE, Curson, DA. Long term depot antipsychotics: a risk–benefit assessment. Drug Saf 1994; 10: 464–79.
3 Barnes, TRE, Shingleton-Smith, A., Paton, C. Antipsychotic long-acting injections: prescribing practice in the UK. Br J Psychiatry 2009; 195 (suppl): s3742.
4 David, AS, Adams, C. Depot antipsychotic medication in the treatment of patients with schizophrenia: (1) meta-review; (2) patient and nurse attitudes. Health Technol Assess 2001; 5: 179.
5 Patel, MX, David, AS. Why aren't depot antipsychotics prescribed more often and what can be done about it? Adv Psychiatr Treat 2005; 11: 203–11.
6 Patel, MX, Haddad, PM, Chaudhry, IB, McLoughlin, S., Husain, N., David, AS. Psychiatrists' use, knowledge and attitudes to first- and second-generation antipsychotic long-acting injections: comparisons over 5 years. J Psychopharmacol 2010; 24: 1473–82.
7 National Institute for Health and Clinical Excellence. Schizophrenia: Core Interventions in the Treatment and Management of Schizophrenia in Adults in Primary and Secondary Care (Update), CG82. NICE, 2009.
8 Barnes, TRE. Evidence-based guidelines for the pharmacological treatment of schizophrenia: recommendations from the British Association for Psychopharmacology. J Psychopharmacol 2011; 25: 567620.
9 Adams, CE, Fenton, MKP, Quraishi, S., David, AS. Systematic meta-review of depot antipsychotic drugs for people with schizophrenia. Br J Psychiatry 2001; 179: 290–9.
10 Haddad, PM, Taylor, M., Niaz, OS. First-generation antipsychotic long-acting injections v. oral antipsychotics in schizophrenia: systematic review of randomised controlled trials and observational studies. Br J Psychiatry 2009; 195: s208.
11 Leucht, C., Heres, S., Kane, JM, Kissling, W., Davis, JM, Leucht, S. Oral versus depot antipsychotic drugs for schizophrenia – a critical systematic review and meta-analysis of randomised long-term trials. Schizophr Res 2011; 127: 8392.
12 Rosenheck, RA, Krystal, JH, Lew, R., Barnett, PG, Fiore, L., Valley, D., et al Long-acting risperidone and oral antipsychotics in unstable schizophrenia. N Engl J Med 2011; 364: 842–51.
13 Leucht, S., Tardy, M., Komossa, K., Heres, S., Kissling, W., Salanti, G., et al Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: a systematic review and meta-analysis. Lancet 2012; 379: 2063–71.
14 Kishimoto, T., Robenzadeh, A., Leucht, C., Leucht, S., Watanabe, K., Mimura, M., et al Long-acting injectable vs oral antipsychotics for relapse prevention in schizophrenia: a meta-analysis of randomized trials. Schizophr Bull 2013; Jan 2 (Epub ahead of print).
15 Zhu, B., Ascher-Svanum, H., Shi, L., Faries, D., Montgomery, W., Marder, SR. Time to discontinuation of depot and oral first-generation antipsychotics in the usual care of schizophrenia. Psychiatr Serv 2008; 59: 315–7.
16 Tiihonen, J., Haukka, J., Taylor, M., Haddad, PM, Patel, MX, Korhonen, P. A nationwide cohort study of oral and depot antipsychotics after first hospitalization for schizophrenia. Am J Psychiatry 2011; 168: 603–9.
17 Grimaldi-Bensouda, L., Rouillon, F., Astruc, B., Rossignol, M., Benichou, J., Falissard, B., et al Does long-acting injectable risperidone make a difference to the real-life treatment of schizophrenia? Results of the Cohort for the General study of Schizophrenia (CGS). Schizophr Res 2012; 134: 187–94.
18 Bitter, I., Katona, L., Zámbori, J., Takács, P., Fehér, L., Diels, J., et al Comparative effectiveness of depot and oral second generation antipsychotic drugs in schizophrenia: a nationwide study in Hungary. Eur Neuropsychopharmacol 2013; Mar 7 (Epub ahead of print).
19 Lambert, T., Olivares, JM, Peuskens, J., Desouza, C., Kozma, CM, Otten, P., et al Effectiveness of injectable risperidone long-acting therapy for schizophrenia: data from the US, Spain, Australia, and Belgium. Ann Gen Psychiatry 2011; 10: 10.
20 Peng, X., Ascher-Svanum, H., Faries, D., Conley, RR, Schuh, KJ. Decline in hospitalization risk and health care cost after initiation of depot antipsychotics in the treatment of schizophrenia. Clinicoecon Outcomes Res 2011; 3: 914.
21 Bowen, J., Barnes, TRE. The clinical characteristics of schizophrenic patients consenting and not consenting to a placebo-controlled trial. Hum Psychopharmacol 1994; 9: 423–33.
22 Jones, PB, Barnes, TRE, Davies, L., Dunn, G., Lloyd, H., Hayhurst, KP, et al Randomized controlled trial of the effect on quality of life of second- vs first-generation antipsychotic drugs in schizophrenia. Arch Gen Psychiatry 2006; 63: 1079–87.
23 Lewis, SW, Barnes, TRE, Davies, L., Murray, RM, Dunn, G., Hayhurst, KP, et al Randomized controlled trial of effect of prescription of clozapine versus other second-generation antipsychotic drugs in resistant schizophrenia. Schizophr Bull 2006; 32: 715–23.
24 American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (4th edn) (DSM-IV). APA, 1994.
25 Heinrichs, DW, Hanlon, TE, Carpenter, WT. The Quality of Life Scale: an instrument for rating the schizophrenic deficit syndrome. Schizophr Bull 1984; 10: 388–98.
26 Kay, SR, Fiszbein, A., Opler, LA. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull 1987; 13: 261–76.
27 Addington, D., Addington, J., Schissel, B. A depression rating scale for schizophrenics. Schizophr Res 1990; 3: 247–51.
28 Hogan, TP, Awad, AG, Eastwood, R. A self-report scale predictive of drug compliance in schizophrenics: reliability and discriminative validity. Psychol Med 1983; 13: 177–83.
29 Hayward, P., Chan, N., Kemp, R., Youle, S., David, A. Medication self-management: a preliminary report on an intervention to improve medication compliance. J Ment Health 1995; 4: 511–7.
30 Yusufi, B., Mukherjee, S., Flanagan, R., Paton, C., Dunn, G., Page, E., et al Prevalence and nature of side effects during clozapine maintenance treatment and the relationship with clozapine dose and plasma concentration. Int Clin Psychopharmacol 2007; 22: 238–43.
31 Ohlsen, RI, Williamson, R., Yusufi, B., Mullan, J., Irving, D., Mukherjee, S., et al Interrater reliability of the Antipsychotic Non-Neurological Side-Effects Rating Scale measured in patients treated with clozapine. J Psychopharmacol 2008; 22: 323–9.
32 Simpson, G., Angus, J. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand 1970; 45: 11–9.
33 Barnes, TR. A rating scale for drug-induced akathisia. Br J Psychiatry 1989; 154: 672–6.
34 Guy, W. ECDEU Assessment Manual for Psychopharmacology. Revised DHEW Pub. (ADM). National Institute for Mental Health, 1976.

Effect of prior treatment with antipsychotic long-acting injection on randomised clinical trial treatment outcomes

  • Thomas R. E. Barnes (a1), Richard J. Drake (a2), Graham Dunn (a3), Karen P. Hayhurst (a2), Peter B. Jones (a4) and Shôn W. Lewis (a5)...

Metrics

Altmetric attention score

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed

Effect of prior treatment with antipsychotic long-acting injection on randomised clinical trial treatment outcomes

  • Thomas R. E. Barnes (a1), Richard J. Drake (a2), Graham Dunn (a3), Karen P. Hayhurst (a2), Peter B. Jones (a4) and Shôn W. Lewis (a5)...
Submit a response

eLetters

No eLetters have been published for this article.

×

Reply to: Submit a response


Your details


Conflicting interests

Do you have any conflicting interests? *